{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T09:09:44Z","timestamp":1774084184529,"version":"3.50.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3,21]]},"DOI":"10.7759\/cureus.105578","type":"journal-article","created":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T08:33:46Z","timestamp":1774082026000},"source":"Crossref","is-referenced-by-count":0,"title":["Cardiovascular Events and Management Strategies Including Tyrosine Kinase Inhibitor Switching, Dose Reduction, and Discontinuation in Chronic Myeloid Leukemia: A Single-Center Retrospective Study"],"prefix":"10.7759","author":[{"given":"Nobue","family":"Sato","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryo","family":"Yoshimaru","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong-Mei","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirotaka","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"SungGi","family":"Chi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kensuke","family":"Matsuda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yosuke","family":"Minami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junichiro","family":"Yuda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.64.8899","article-title":"Final 5-year study results of DASISION: the dasatinib versus imatinib study in treatment-na\u00efve chronic myeloid leukemia patients trial","volume":"34","author":"Cortes JE","year":"2016","unstructured":"Cortes JE, Saglio G, Kantarjian HM, et al.. Final 5-year study results of DASISION: the dasatinib versus imatinib study in treatment-na\u00efve chronic myeloid leukemia patients trial. J Clin Oncol. 2016, 34:2333-40. 10.1200\/JCO.2015.64.8899","journal-title":"J Clin Oncol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-01111-2","article-title":"Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis","volume":"35","author":"Kantarjian HM","year":"2021","unstructured":"Kantarjian HM, Hughes TP, Larson RA, et al.. Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis. Leukemia. 2021, 35:440-53. 10.1038\/s41375-020-01111-2","journal-title":"Leukemia"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.74.7162","article-title":"Bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia: results from the randomized BFORE trial","volume":"36","author":"Cortes JE","year":"2018","unstructured":"Cortes JE, Gambacorti-Passerini C, Deininger MW, et al.. Bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia: results from the randomized BFORE trial. J Clin Oncol. 2018, 36:231-7. 10.1200\/JCO.2017.74.7162","journal-title":"J Clin Oncol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-09-739086","article-title":"Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial","volume":"132","author":"Cortes JE","year":"2018","unstructured":"Cortes JE, Kim DW, Pinilla-Ibarz J, et al.. Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial. Blood. 2018, 132:393-404. 10.1182\/blood-2016-09-739086","journal-title":"Blood"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021012082","article-title":"Ponatinib dose-ranging study in chronic-phase chronic myeloid leukemia: a randomized, open-label phase 2 clinical trial","volume":"138","author":"Cortes J","year":"2021","unstructured":"Cortes J, Apperley J, Lomaia E, et al.. Ponatinib dose-ranging study in chronic-phase chronic myeloid leukemia: a randomized, open-label phase 2 clinical trial. Blood. 2021, 138:2042-50. 10.1182\/blood.2021012082","journal-title":"Blood"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.68.2914","article-title":"Long-term follow-up of the French stop imatinib (STIM1) study in patients with chronic myeloid leukemia","volume":"35","author":"Etienne G","year":"2017","unstructured":"Etienne G, Guilhot J, Rea D, et al.. Long-term follow-up of the French stop imatinib (STIM1) study in patients with chronic myeloid leukemia. J Clin Oncol. 2017, 35:298-305. 10.1200\/JCO.2016.68.2914","journal-title":"J Clin Oncol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.11406\/rinketsu.59.747","article-title":"Chronic myeloid leukemia: state-of-the-art management","volume":"59","author":"Takahashi N","year":"2018","unstructured":"Takahashi N. Chronic myeloid leukemia: state-of-the-art management. Rinsho Ketsueki. 2018, 59:747-54. 10.11406\/rinketsu.59.747","journal-title":"Rinsho Ketsueki"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-09-742205","article-title":"Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia: interim analysis of the STOP 2G-TKI study","volume":"129","author":"Rea D","year":"2017","unstructured":"Rea D, Nicolini FE, Tulliez M, et al.. Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia: interim analysis of the STOP 2G-TKI study. Blood. 2017, 129:846-54. 10.1182\/blood-2016-09-742205","journal-title":"Blood"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(15)00127-1","article-title":"Ponatinib as first-line treatment for patients with chronic myeloid leukaemia in chronic phase: a phase 2 study","volume":"2","author":"Jain P","year":"2015","unstructured":"Jain P, Kantarjian H, Jabbour E, et al.. Ponatinib as first-line treatment for patients with chronic myeloid leukaemia in chronic phase: a phase 2 study. Lancet Haematol. 2015, 2:e376-83. 10.1016\/S2352-3026(15)00127-1","journal-title":"Lancet Haematol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14608","article-title":"Comparative analysis of pulmonary hypertension in patients treated with imatinib, nilotinib and dasatinib","volume":"177","author":"Minami M","year":"2017","unstructured":"Minami M, Arita T, Iwasaki H, et al.. Comparative analysis of pulmonary hypertension in patients treated with imatinib, nilotinib and dasatinib. Br J Haematol. 2017, 177:578-87. 10.1111\/bjh.14608","journal-title":"Br J Haematol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2015.5932","article-title":"Association between BCR-ABL tyrosine kinase inhibitors for chronic myeloid leukemia and cardiovascular events, major molecular response, and overall survival: a systematic review and meta-analysis","volume":"2","author":"Douxfils J","year":"2016","unstructured":"Douxfils J, Haguet H, Mullier F, Chatelain C, Graux C, Dogn\u00e9 JM. Association between BCR-ABL tyrosine kinase inhibitors for chronic myeloid leukemia and cardiovascular events, major molecular response, and overall survival: a systematic review and meta-analysis. JAMA Oncol. 2016, 2:625-32. 10.1001\/jamaoncol.2015.5932","journal-title":"JAMA Oncol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2015.82","article-title":"Incidence and relevance of QTc-interval prolongation caused by tyrosine kinase inhibitors","volume":"112","author":"Kloth JS","year":"2015","unstructured":"Kloth JS, Pagani A, Verboom MC, et al.. Incidence and relevance of QTc-interval prolongation caused by tyrosine kinase inhibitors. Br J Cancer. 2015, 112:1011-6. 10.1038\/bjc.2015.82","journal-title":"Br J Cancer"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1253\/circj.CJ-19-0342","article-title":"JCS 2017\/JHFS 2017 guideline on diagnosis and treatment of acute and chronic heart failure - digest version","volume":"83","author":"Tsutsui H","year":"2019","unstructured":"Tsutsui H, Isobe M, Ito H, et al.. JCS 2017\/JHFS 2017 guideline on diagnosis and treatment of acute and chronic heart failure - digest version. Circ J. 2019, 83:2084-184. 10.1253\/circj.CJ-19-0342","journal-title":"Circ J"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.5551\/jat.19356","article-title":"Predicting coronary heart disease using risk factor categories for a Japanese urban population, and comparison with the Framingham risk score: the Suita study","volume":"21","author":"Nishimura K","year":"2014","unstructured":"Nishimura K, Okamura T, Watanabe M, et al.. Predicting coronary heart disease using risk factor categories for a Japanese urban population, and comparison with the Framingham risk score: the Suita study. J Atheroscler Thromb. 2014, 21:784-98. 10.5551\/jat.19356","journal-title":"J Atheroscler Thromb"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehab309","article-title":"SCORE2 risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in Europe","volume":"42","author":"Hageman S","year":"2021","unstructured":"Hageman S, Pennells L, Ojeda F, et al.. SCORE2 risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in Europe. Eur Heart J. 2021, 42:2439-54. 10.1093\/eurheartj\/ehab309","journal-title":"Eur Heart J"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehab312","article-title":"SCORE2-OP risk prediction algorithms: estimating incident cardiovascular event risk in older persons in four geographical risk regions","volume":"42","author":"de Vries TI","year":"2021","unstructured":"de Vries TI, Cooney MT, Selmer RM, et al.. SCORE2-OP risk prediction algorithms: estimating incident cardiovascular event risk in older persons in four geographical risk regions. Eur Heart J. 2021, 42:2455-67. 10.1093\/eurheartj\/ehab312","journal-title":"Eur Heart J"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2012.244","article-title":"Investigation of the freely available easy-to-use software 'EZR' for medical statistics","volume":"48","author":"Kanda Y","year":"2013","unstructured":"Kanda Y. Investigation of the freely available easy-to-use software 'EZR' for medical statistics. Bone Marrow Transplant. 2013, 48:452-8. 10.1038\/bmt.2012.244","journal-title":"Bone Marrow Transplant"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12051242","article-title":"Long-term survival, vascular occlusive events and efficacy biomarkers of first-line treatment of CML: a meta-analysis","volume":"12","author":"Haguet H","year":"2020","unstructured":"Haguet H, Graux C, Mullier F, Dogn\u00e9 JM, Douxfils J. Long-term survival, vascular occlusive events and efficacy biomarkers of first-line treatment of CML: a meta-analysis. Cancers (Basel). 2020, 12:1242. 10.3390\/cancers12051242","journal-title":"Cancers (Basel)"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12040826","article-title":"Cardiovascular toxicity of tyrosine kinase inhibitors used in chronic myeloid leukemia: an analysis of the FDA Adverse Event Reporting System database (FAERS)","volume":"12","author":"Cirmi S","year":"2020","unstructured":"Cirmi S, El Abd A, Letinier L, Navarra M, Salvo F. Cardiovascular toxicity of tyrosine kinase inhibitors used in chronic myeloid leukemia: an analysis of the FDA Adverse Event Reporting System database (FAERS). Cancers (Basel). 2020, 12:826. 10.3390\/cancers12040826","journal-title":"Cancers (Basel)"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.62.4718","article-title":"Tyrosine kinase inhibitor-associated cardiovascular toxicity in chronic myeloid leukemia","volume":"33","author":"Moslehi JJ","year":"2015","unstructured":"Moslehi JJ, Deininger M. Tyrosine kinase inhibitor-associated cardiovascular toxicity in chronic myeloid leukemia. J Clin Oncol. 2015, 33:4210-8. 10.1200\/JCO.2015.62.4718","journal-title":"J Clin Oncol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24360","article-title":"Long-term evaluation of cardiac and vascular toxicity in patients with Philadelphia chromosome-positive leukemias treated with bosutinib","volume":"91","author":"Cortes JE","year":"2016","unstructured":"Cortes JE, Jean Khoury H, Kantarjian H, et al.. Long-term evaluation of cardiac and vascular toxicity in patients with Philadelphia chromosome-positive leukemias treated with bosutinib. Am J Hematol. 2016, 91:606-16. 10.1002\/ajh.24360","journal-title":"Am J Hematol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.38.7522","article-title":"Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial","volume":"30","author":"Cortes JE","year":"2012","unstructured":"Cortes JE, Kim DW, Kantarjian HM, et al.. Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial. J Clin Oncol. 2012, 30:3486-92. 10.1200\/JCO.2011.38.7522","journal-title":"J Clin Oncol"},{"key":"ref23","article-title":"Liposomes ameliorate crizotinib- and nilotinib-induced inhibition of the cardiac IKr channel and QTc prolongation","volume":"34","author":"Shopp GM","year":"2014","unstructured":"Shopp GM, Helson L, Bouchard A, Salvail D, Majeed M. Liposomes ameliorate crizotinib- and nilotinib-induced inhibition of the cardiac IKr channel and QTc prolongation. Anticancer Res. 2014, 34:4733-40.","journal-title":"Anticancer Res"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1177\/2047487316653709","article-title":"2016 European guidelines on cardiovascular disease prevention in clinical practice: the sixth joint task force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of 10 societies and by invited experts): developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR)","volume":"23","author":"Piepoli MF","year":"2016","unstructured":"Piepoli MF, Hoes AW, Agewall S, et al.. 2016 European guidelines on cardiovascular disease prevention in clinical practice: the sixth joint task force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of 10 societies and by invited experts): developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur J Prev Cardiol. 2016, 23:NP1-96. 10.1177\/2047487316653709","journal-title":"Eur J Prev Cardiol"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1007\/s11936-016-0452-z","article-title":"Anti-VEGF-induced hypertension: a review of pathophysiology and treatment options","volume":"18","author":"Brinda BJ","year":"2016","unstructured":"Brinda BJ, Viganego F, Vo T, Dolan D, Fradley MG. Anti-VEGF-induced hypertension: a review of pathophysiology and treatment options. Curr Treat Options Cardiovasc Med. 2016, 18:33. 10.1007\/s11936-016-0452-z","journal-title":"Curr Treat Options Cardiovasc Med"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.674748","article-title":"Arterial hypertension and tyrosine kinase inhibitors in chronic myeloid leukemia: a systematic review and meta-analysis","volume":"12","author":"Mulas O","year":"2021","unstructured":"Mulas O, Caocci G, Mola B, La Nasa G. Arterial hypertension and tyrosine kinase inhibitors in chronic myeloid leukemia: a systematic review and meta-analysis. Front Pharmacol. 2021, 12:674748. 10.3389\/fphar.2021.674748","journal-title":"Front Pharmacol"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.2147\/VHRM.S108874","article-title":"Cardiovascular toxicities of BCR-ABL tyrosine kinase inhibitors in chronic myeloid leukemia: preventive strategies and cardiovascular surveillance","volume":"13","author":"Aghel N","year":"2017","unstructured":"Aghel N, Delgado DH, Lipton JH. Cardiovascular toxicities of BCR-ABL tyrosine kinase inhibitors in chronic myeloid leukemia: preventive strategies and cardiovascular surveillance. Vasc Health Risk Manag. 2017, 13:293-303. 10.2147\/VHRM.S108874","journal-title":"Vasc Health Risk Manag"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2022.100968","article-title":"Long-term safety review of tyrosine kinase inhibitors in chronic myeloid leukemia - what to look for when treatment-free remission is not an option","volume":"56","author":"Lipton JH","year":"2022","unstructured":"Lipton JH, Br\u00fcmmendorf TH, Gambacorti-Passerini C, Garcia-Guti\u00e9rrez V, Deininger MW, Cortes JE. Long-term safety review of tyrosine kinase inhibitors in chronic myeloid leukemia - what to look for when treatment-free remission is not an option. Blood Rev. 2022, 56:100968. 10.1016\/j.blre.2022.100968","journal-title":"Blood Rev"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-018-3412-8","article-title":"Features of vascular adverse events in Japanese patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a retrospective study of the CML Cooperative Study Group database","volume":"97","author":"Fujioka I","year":"2018","unstructured":"Fujioka I, Takaku T, Iriyama N, et al.. Features of vascular adverse events in Japanese patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a retrospective study of the CML Cooperative Study Group database. Ann Hematol. 2018, 97:2081-8. 10.1007\/s00277-018-3412-8","journal-title":"Ann Hematol"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(19)30094-8","article-title":"De-escalation of tyrosine kinase inhibitor therapy before complete treatment discontinuation in patients with chronic myeloid leukaemia (DESTINY): a non-randomised, phase 2 trial","volume":"6","author":"Clark RE","year":"2019","unstructured":"Clark RE, Polydoros F, Apperley JF, et al.. De-escalation of tyrosine kinase inhibitor therapy before complete treatment discontinuation in patients with chronic myeloid leukaemia (DESTINY): a non-randomised, phase 2 trial. Lancet Haematol. 2019, 6:e375-83. 10.1016\/S2352-3026(19)30094-8","journal-title":"Lancet Haematol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/411348-cardiovascular-events-and-management-strategies-including-tyrosine-kinase-inhibitor-switching-dose-reduction-and-discontinuation-in-chronic-myeloid-leukemia-a-single-center-retrospective-study","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T08:33:47Z","timestamp":1774082027000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/411348-cardiovascular-events-and-management-strategies-including-tyrosine-kinase-inhibitor-switching-dose-reduction-and-discontinuation-in-chronic-myeloid-leukemia-a-single-center-retrospective-study"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,21]]},"references-count":30,"URL":"https:\/\/doi.org\/10.7759\/cureus.105578","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3,21]]}}}